Sandy Macrae Sangamo Therapeutics, Inc (SGMO) insider trading activity

Sandy Macrae is PRESIDENT, CEO AND DIRECTOR of SANGAMO THERAPEUTICS, INC. Currently has a direct ownership of 2.1 Million shares of SGMO, which is worth approximately $2.37 Million. The most recent transaction as insider was on Jan 22, 2025, when has been sold 412,584 shares (Common Stock) at a price of $1.15 per share, resulting in proceeds of $474,471. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 2.1M

17.05% 3M change

19.15% 12M change

Total Value Held $2.37 Million

Sandy Macrae Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 22 2025	SELL Payment of exercise price or tax liability	$474,471 $1.15 p/Share	412,584 Reduced 16.45%	2,095,999 Common Stock
Nov 25 2024	SELL Payment of exercise price or tax liability	$20,645 $1.94 p/Share	10,642 Reduced 0.42%	2,508,583 Common Stock
Nov 24 2024	SELL Payment of exercise price or tax liability	$14,049 $1.88 p/Share	7,473 Reduced 0.3%	2,519,225 Common Stock
Aug 25 2024	SELL Payment of exercise price or tax liability	$6,443 $0.86 p/Share	7,492 Reduced 0.3%	2,526,698 Common Stock
Aug 24 2024	SELL Payment of exercise price or tax liability	$4,524 $0.86 p/Share	5,261 Reduced 0.21%	2,534,190 Common Stock
May 25 2024	SELL Payment of exercise price or tax liability	$4,495 $0.6 p/Share	7,492 Reduced 0.29%	2,539,451 Common Stock
May 24 2024	SELL Payment of exercise price or tax liability	$3,156 $0.6 p/Share	5,261 Reduced 0.21%	2,546,943 Common Stock
Feb 25 2024	SELL Payment of exercise price or tax liability	$27,297 $1.13 p/Share	24,157 Reduced 0.94%	2,552,204 Common Stock
Feb 24 2024	SELL Payment of exercise price or tax liability	$18,209 $1.13 p/Share	16,115 Reduced 0.62%	2,576,361 Common Stock
Jan 22 2024	BUY Grant, award, or other acquisition	-	2,000,000 Added 43.55%	2,592,476 Common Stock
Nov 25 2023	SELL Payment of exercise price or tax liability	$3,956 $0.38 p/Share	10,411 Reduced 1.73%	592,476 Common Stock
Aug 25 2023	SELL Payment of exercise price or tax liability	$8,016 $0.77 p/Share	10,411 Reduced 1.7%	602,887 Common Stock
May 25 2023	SELL Payment of exercise price or tax liability	$13,846 $1.33 p/Share	10,411 Reduced 1.67%	613,298 Common Stock
Feb 25 2023	SELL Payment of exercise price or tax liability	$145,680 $2.66 p/Share	54,767 Reduced 8.07%	623,709 Common Stock
Feb 24 2023	BUY Grant, award, or other acquisition	-	157,300 Added 18.82%	678,476 Common Stock
Feb 25 2022	SELL Payment of exercise price or tax liability	$294,351 $5.9 p/Share	49,890 Reduced 14.37%	297,176 Common Stock
Feb 25 2022	BUY Grant, award, or other acquisition	-	224,000 Added 30.06%	521,176 Common Stock
Feb 25 2021	SELL Payment of exercise price or tax liability	$395,130 $11.19 p/Share	35,311 Reduced 14.47%	208,691 Common Stock
Feb 25 2021	BUY Grant, award, or other acquisition	-	138,375 Added 28.51%	347,066 Common Stock
Jan 24 2021	SELL Payment of exercise price or tax liability	$59,456 $14.95 p/Share	3,977 Reduced 1.6%	244,002 Common Stock

Sandy Macrae

PRESIDENT, CEO AND DIRECTOR

Brisbane, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SGMO shares.

Notify only if

Value

Insider Trading

Get notified when an Sangamo Therapeutics, Inc insider buys or sells SGMO shares.

Notify only if

Operation

Value

Type

News

Receive news related to SANGAMO THERAPEUTICS, INC

Track Activities on SGMO

Account